1
15
↑1
↓15
—0
Evidence suggests Semaglutide maydecreaseCardiovascular events.
12 studies (16 claims)
Moderate consensus
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| glucagon-like peptide-1 receptor agonists (GLP-1RA), liraglutide and semaglutide | Decreases - showed a reduction | cardiovascular events | Human | patients with type 2 diabetes mellitus | — | Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. |
| semaglutide 2.4 mg once-weekly | Decreases - reduced the risk | major cardiovascular events and heart failure-related events | Human | individuals with obesity | — | Incretin-based therapies for the treatment of obesity-related diseases. |
| GLP-1 RA semaglutide | Decreases - superior | major adverse cardiovascular events | Human | — | — | What have we learnt from "real world" data, observational studies and meta-analyses. |
| highly potent incretin receptor agonists semaglutide and tirzepatide | Decreases - reduced risk | cardiovascular events | Human | patients with type 2 diabetes and obesity | — | GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. |
| semaglutide | Decreases - reduced | cardiovascular events | Human | patients with type 2 diabetes mellitus with or at risk for cardiovascular disease | — | Cardiovascular safety outcomes of new antidiabetic therapies. |
| semaglutide | Decreases - showed a reduction | cardiovascular events and death | Human | — | — | Cardiovascular safety outcomes of new antidiabetic therapies. |
| semaglutide | Decreases - led to a reduction in | major adverse cardiovascular events | Human | patients without diabetes who were either overweight and had preexisting cardiovascular disease or obese | — | Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity? |
| Semaglutide | Decreases - demonstrate a significant reduction in the incidence | major adverse cardiovascular events | Human | participants in the SELECT trial | — | Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment. |
| semaglutide | Decreases - was effective in reducing major adverse cardiovascular events | major adverse cardiovascular events | Human | — | — | A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. |
| semaglutide | Decreases - significant reductions | major cardiovascular (CV) events | HumanMolecular | — | — | After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? |
| semaglutide | Increases - difference of RMSTs for primary composite endpoint of cardiovascular events | primary composite endpoint of cardiovascular events | Human | patients in SUSTAIN-6 trial | — | Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio. |
| semaglutide | Decreases - decrease the risk of major adverse cardiovascular events | risk of major adverse cardiovascular events | Human | — | — | Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio. |